Thyroid Hormones in Dilated Cardiomyopathy: Is It a Promising Therapeutic Option?

Abstract

Dilated cardiomyopathy (DCM) is chronic heart muscle disease characterized by progressive ventricular enlargement and contractile dysfunction involving either left or both ventricles [1,2]. It is considered one of the leading causes of heart failure with reduced ejection fraction (HFrEF) worldwide. The reported prevalence of DCM in Europe and North America is ~36 cases per 100,000 population, which is clearly lower in Eastern Asia (i.e., 14 cases per 100,000 in Japan), and might be higher in Africa and Latin [3].